Split tablet dosing of Levodopa/Carbidopa/Entacapone 100mg/25mg/200mg in treating Chinese patients with early Parkinson’s disease: a single-center, prospective cohort study
Objective: To investigate split tablet dosing of Levodopa/Carbidopa/Entacapone (LCE) 100mg/25mg/200mg in treating Chinese patients with early Parkinson’s disease (PD). Background: LCE is a treatment option…Multidimensional Assessment of Levodopa/Carbidopa/Entacapone Gel (LECIG) Therapy in Parkinson’s Disease: Perspectives of Patients, Clinicians, and Caregivers
Objective: To evaluate the impact of Levodopa/Entacapone/Carbidopa Gel (LECIG) therapy on Parkinson’s disease (PD) patients, their caregivers, and clinicians over six months. Background: Advanced PD…Three-Year Single-Center Experience with Levodopa–Entacapone–Carbidopa Intestinal Gel in Advanced Parkinson’s Disease
Objective: To evaluate the efficacy of Levodopa-Entacapone-Carbidopa Intestinal Gel (LECIG) in advanced Parkinson’s Disease (APD). Background: LECIG infusion has been available in Romania since 2021.…Comparative analysis of opicapone and entacapone in the management of motor fluctuations in patients with Parkinson’s disease, from clinical trials to healthcare resource usage
Objective: To assess the differences between two catechol-O-methyltransferase (COMT) inhibitors, opicapone (OPC) and entacapone (ENT). Background: Opicapone and ENT are COMT inhibitors developed as adjunct…Levodopa-Entacapone-Carbidopa Intestinal Gel Treatment In Parkinson’s Disease: A Single-Center Retrospective Chart Study
Objective: The objectives of this chart study were to evaluate adaptations in medication and flow rates and adverse events in patients with Parkinson’s disease (PD)…Levodopa-Entacapone-Carbidopa Intestinal Gel in the treatment of advanced Parkinson’s disease: a two-year experience
Objective: To evaluate the efficacy of Levodopa-Entacapone-Carbidopa Intestinal Gel (LECIG) in the treatment of patients with advanced Parkinson’s Disease (APD). Background: The continuous enteral infusion…Efficacy of levodopa/carbidopa/entacapone replacement of levodopa/dopa decarboxylase inhibitors in treatment of Chinese Parkinson’s disease patients with wearing-off: a multicenter, randomized controlled, open label study
Objective: This study aimed to investigate the efficacy and safety comparison between LCE and Pramexol in Chinese PD patients with the wearing-off phenomenon. Background: Wearing…Impact of oral COMT-inhibitors on gut microbiota and biologically active microbial metabolites in patients with Parkinson’s Disease
Objective: To investigate if we were able to reproduce our previous findings in an independent patient cohort and whether such a correlation also exists in…Sustained release triple drug loaded Microbaloons for management of Parkinson’s Disease
Objective: It is hypothesized that a drug delivery system that provides controlled and sustained release of PD drugs would afford better management of PD. Hollow…A novel non-nitrocatechol COMT inhibitor ODM-104 shows superior pharmacodynamic effects to entacapone
Objective: ODM-104 is a novel non-nitrocatechol catechol-O-methyltransferase (COMT) inhibitor that is undergoing clinical evaluation for Parkinson’s disease (PD). This study investigated the pharmacodynamic effects of…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.